In response to nosedives in Hewlett-Packard Co. and Apple Inc. counteract gains among retailers in the course of corporate earnings, U.S. stocks were little changed near all-time highs on Wednesday.
Hewlett-Packard fell over 9.9 percent after saying earnings will be hurt by the rising dollar. Apple declined 2.6 percent after technology shares dropped 0.7 percent.
Yellen repeated that stance before lawmakers a second day.
Insights about some real movers of the market that lately hits 52-week high, amid Thursday’s exchange are depicted underneath:
Pharmacyclics Inc. (NASDAQ:PCYC)’s shares skyrocketed 16.86% and led the share to close at $220.22, hitting new 52-week high of $231.09, soon after a biopharmaceutical company, weighs sale of $15 Billion U.S. Drugmaker. The Sunnyvale, California-based drugmaker has attracted interest from companies counting Johnson & Johnson and Novartis AG, the people said, asking not to be identified discussing private information. Pharmacyclics may fetch $17 billion to $18 billion in a possible sale, the people said, adding that deliberations are at an early stage and may not lead to a deal. An $18 billion offer would represent about a 25 percent premium to the company’s market value at the close Tuesday.
Pharmacyclics Inc. (NASDAQ:PCYC), a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally.
Shares of ICON Public Limited Company (NASDAQ:ICLR), jumped nearly 10.07% and closed at $67.75, hitting new 52-week high of $68.83, soon after a contract research organization, stated its financial results for the fourth quarter and full year ended December 31, 2014. In the fourth quarter net proceed grew 13.0% year on year to $390.1 million from $345.2 million in the same quarter last year. Revenue from operations before non-recurring charges was $60.4 million or 15.5% of proceed, contrast to $38.7 million or 11.2% for the same quarter last year. Net revenue before non-recurring charges was $54 million or 87 cents per share on a diluted basis, contrast with $33.5 million or 53 cents per share for the same quarter last year.
Full year net proceeds for 2014 raised 12.5% to $1,503 million from $1,336 million in 2013. Full year revenue from operations before non-recurring charges was $211.1 million or 14.0% of proceed, contrast with revenue from operations before non-recurring charges of $130.2 million or 9.7% of proceed in the previous year.
ICON Public Limited Company (NASDAQ:ICLR), is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the planned development, administration and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.
Fleetmatics Group PLC (NYSE:FLTX), surged 13.34% to close at $43.00, hitting new 52-week high of $43.00, soon after the news release that a leading global provider of mobile workforce solutions for service-based businesses of all sizes delivered as software-as-a-service (SaaS), declared financial results for its fourth quarter and full year ended December 31, 2014. Total proceed for the fourth quarter of 2014 was $64.0 million, an raise of 28% contrast to $50.1 million for the fourth quarter of 2013. GAAP net revenue for the fourth quarter of 2014 was $12.4 million, or $0.32 per diluted share, contrast to $16.2 million, or $0.42 per diluted share, for the fourth quarter of 2013. Non-GAAP1 adjusted earnings for the fourth quarter of 2014 was $17.0 million, or $0.44 per diluted share, contrast to $8.9 million, or $0.23 per diluted share, for the fourth quarter of 2013. Adjusted EBITDA1 for the fourth quarter of 2014 was $24.2 million, an raise of 50% contrast to $16.1 million for the fourth quarter of 2013. Adjusted EBITDA1 margin for the fourth quarter of 2014 was 37.7%, contrast to 32.2% for the fourth quarter of 2013. As of December 31, 2014, the Company had cash of $175.4 million contrast to $161.0 million at September 30, 2014. During the fourth quarter of 2014, the Company generated free cash flow of $14.8 million contrast to negative $7.1 million in the fourth quarter of 2013.
“Without question, 2014 was a year of tremendous progress throughout the Company,” said Jim Travers, Chairman and Chief Executive Officer of Fleetmatics. “We opened up several new geographic markets and introduced innovative new cloud based solutions for fleet and field service administration all while delivering significantly improved financial results. Looking ahead, we are focused on extending our leadership position in North America, increasing our addressable market by expanding into mainland Europe, and deepening our relationship with our customers through adjacent applications that further leverage our SaaS platform.”
Fleetmatics Group PLC (NYSE:FLTX), is a leading global provider of mobile workforce solutions for service-based businesses of all sizes delivered as software-as-a-service (SaaS). Our solutions enable businesses to meet the challenges associated with managing local fleets, and improve the productivity of their mobile workforces, by extracting actionable business intelligence from real-time and historical vehicle and driver behavioral data.
Shares of the PTC Therapeutics, Inc. (NASDAQ:PTCT), gained 3.41% & closed at $73.59, hitting new 52-week high of $74.93, as a biopharmaceutical company, declared that administration will present a company update at the following conferences:
Cowen and Company 35th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on Monday, March 2nd.
27th Annual ROTH Conference at The Ritz Carlton in Laguna Niguel, CA on Monday March 9th.
Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, FL on Tuesday, March 10th.
PTC Therapeutics, Inc. (NASDAQ:PTCT), is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs that target post-transcriptional control processes.
